View Post

PBM Delays for Cancer Drugs May Risk Lives, Warn Oncologists

In In The News by Barbara Jacoby

By: Alicia Ault From: medscape.com The patient had metastatic kidney cancer, and his oncologist was seeking to treat him with sunitinib malate (Sutent, Pfizer), a preferred first-line oral therapy. But the patient’s pharmacy benefit manager (PBM) refused to cover the cost of the medication. The PBM told the oncologist that the patient’s kidney must first be removed. However, the patient’s …

View Post

Bacteria-Based Drug Delivery System Outperforms Conventional Methods

In In The News by Barbara Jacoby

By: Virginia Tech From: labmanager.com A new drug delivery system could radically expand cancer treatment options An interdisciplinary team of three Virginia Tech faculty members affiliated with the Macromolecules Innovation Institute has created a drug delivery system that could radically expand cancer treatment options. The conventional cancer treatment method of injecting nanoparticle drugs into the bloodstream results in low efficacy. …

View Post

2 Trials, Now Enrolling, Aimed at Improving Breast Cancer Prevention, Diagnosis, and Treatment

In Clinical Trials by Barbara Jacoby

By: Patricia Inacio, PhD From: breastcancer-news.com The University of Hawaiʻi Cancer Center is enrolling participants in two clinical trials to test new ways of preventing and diagnosing breast cancer, as well as improving current treatments. “These trials are very important because breast cancer is a significant issue in Hawaiʻi,” Randall Holcombe, director of the UH Cancer Center said in a press release. “Racial and ethnic minority …

View Post

Aileron Enters Clinical Trial Collaboration With Pfizer To Evaluate ALRN-6924 In Combination With IBRANCE® (Palbociclib) In MDM2-Amplified Cancers

In Clinical Trials by Barbara Jacoby

Source: Aileron Therapeutics, Inc. From: clinicalleader.com Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other diseases, today announced that it has entered into a clinical trial collaboration with Pfizer to evaluate the combination of Aileron’s ALRN-6924 and Pfizer’s palbociclib, also known as IBRANCE®, in MDM2-amplified cancers. Overexpression of MDM2 in …

View Post

Scientists may have found a way to treat cancer without chemotherapy by replicating our body’s own self-destruct system

In In The News by Barbara Jacoby

By: Lisa Schönhaar From: businessinsider.com Every day, millions of cells in our bodies “kill themselves” and are quickly removed. While the mechanism may sound melodramatic, in reality it’s for our own good. This is because the process ensures potentially harmful cells destroy themselves and, as a consequence, we’re protected from disease. Cancer cells, however, can protect themselves from self-destruction by …

View Post

Cancer: Brain-derived compounds show surprising benefits

In In The News by Barbara Jacoby

Source: Veterans Affairs Research Communications From: sciencedaily.com A lab team led by Nobel Prize winner Dr. Andrew Schally at the Miami Veterans Affairs Healthcare System and the University of Miami showed that a synthetic compound based on a brain hormone spurred the growth of cancer cells in Petri dishes but enigmatically had the opposite effect in mice. The surprising discovery, …

View Post

Physician Releases Fresh Perspective on Cancer Treatment in New Book

In In The News by Barbara Jacoby

Dr. Alexandre Rushenas, M.D., lays bare common notions of the disease as a ‘fight’ and draws on the healing power of the cellular response to authentic emotions and unconditional love in “Cancer, I Love You” A Canada-based author and medical doctor who works in emergency medicine has released an inspirational and revolutionary approach to cancer that aims to help others …